<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510740</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-100425</org_study_id>
    <nct_id>NCT04510740</nct_id>
  </id_info>
  <brief_title>Liver Cancer Registry Platform</brief_title>
  <acronym>JADE</acronym>
  <official_title>JADE - Clinical Research Platform on Treatment and Outcome in Patients With Hepatocellular or Cholangiocellular Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is to set up a national, prospective, longitudinal, multicenter&#xD;
      cohort study with associated satellites, a tumor registry platform, to document uniform data&#xD;
      on characteristics, molecular diagnostics, treatment and course of disease, to collect&#xD;
      patient-reported outcomes and to establish a decentralized biobank for patients with&#xD;
      Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      JADE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor&#xD;
      registry platform) with the purpose to record information on the antineoplastic treatment of&#xD;
      HCC or CCC in Germany. The registry will follow patients for up to three years. It will&#xD;
      identify common therapeutic sequences and changes in the treatment of the disease. At&#xD;
      inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous&#xD;
      treatments are collected. During the course of observation data on all systemic treatments,&#xD;
      radiotherapies, surgeries, and outcome are documented.&#xD;
&#xD;
      Health-related quality of life in patients with HCC / CCC will be evaluated for up to three&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Course of treatment (treatment reality).</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>Documentation of anamnestic data and therapy sequences.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response.</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>Documentation of response rates per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival.</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>Documentation of progression-free survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>Documentation of overall survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (Patient-reported outcome, PRO).</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>EORTC QLQ-C30 core questionnaire [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high scale score represents a higher response level: (a) global health status: a high score represents high quality of life, (b) functional scales: a high score represents high/healthy level of functioning, (c) symptom scales/items: a high score represents high level of symptomatology or problems]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carcinoma Health-related quality of life (Patient-reported outcome, PRO).</measure>
    <time_frame>3 years per patient.</time_frame>
    <description>EORTC QLQ-HCC18, the hepatocellular carcinoma specific module / EORTC QLQ-BIL21, the cholangiocarcinoma specific module [European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high score for scales and single items represents a high level of symptomatology or problems].</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Hepatocellular Carcinoma (HCC)</arm_group_label>
    <description>Patients with Hepatocellular Carcinoma (HCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholangiocarcinoma (CCC)</arm_group_label>
    <description>Patients with Cholangiocarcinoma (CCC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physician's choice according to patient's needs.</intervention_name>
    <description>Routine care as per site standard.</description>
    <arm_group_label>Cholangiocarcinoma (CCC)</arm_group_label>
    <arm_group_label>Hepatocellular Carcinoma (HCC)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with hepatocellular carcinoma (HCC), or cholangiocarcinoma (CCC) starting&#xD;
        treatment for early, intermediate or advanced disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early,&#xD;
             intermediate or advanced/metastatic stage&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Signed and dated informed consent (IC):&#xD;
&#xD;
               -  For participation in the PRO module: Before primary locoregional therapy or start&#xD;
                  of first systemic treatment&#xD;
&#xD;
               -  For no participation in the PRO module: No later than 8 weeks after primary&#xD;
                  locoregional therapy or start of first systemic treatment&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no&#xD;
        ablative procedures, no systemic anti-tumoral therapies)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Berg, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter R. Galle, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Mainz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolf P. Hofmann, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Achim Kautz</last_name>
    <role>Study Chair</role>
    <affiliation>Köln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Pereira, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Heilbronn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Potthoff, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Freiburg im Breisgau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Schröder, PD Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Mülheim an der Ruhr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Thimme, Prof.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Freiburg im Breisgau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>iOMEDICO AG</last_name>
    <phone>+49 761 15242-0</phone>
    <email>info@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple sites all over germany</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>iOMEDICO AG</last_name>
      <phone>+49 761 152420</phone>
      <email>info@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

